A recent meta-analysis by Wei et al. showed that [40] SGLT-2 inhibitors effectively improved NAFLD by reducing liver enzymes and liver fat and improving body composition. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.